Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
US Confirms 50% Tariffs on Japan’s Heavy Trucks; Pharma Capped at 15%
The US will apply a 25% additional tariff on heavy trucks and related parts imported from Japan, a White House official told Jiji Press on September 26. Meanwhile, the levy on pharmaceuticals from Japan will be capped at 15% under…
To read the full story
Related Article
- Japan Drug Makers Vetting Impact as Trump Unveils Tariff Details
April 6, 2026
- Trump Signs Off on Up to 100% Tariffs on Drugs; Japan Rate Set at 15%
April 3, 2026
- Japan Will Receive MFN Status on US Drug Tariffs: Akazawa
October 1, 2025
- Generics to Be Exempt from Tariffs under US-Japan Deal: Govt Officials
September 10, 2025
- Japan Govt OKs Economic Package to Counter US Tariff Impact
April 28, 2025
- LDP Tariff Task Force Broadly OKs First Proposal
April 22, 2025
- MHLW on Alert for Potential Tariffs on Osteomalacia, Schizophrenia Meds
April 11, 2025
REGULATORY
- Carvykti Earlier Use Up for Japan Panel Review on June 29
June 23, 2026
- Kampo Industry Calls for Predictable Drug Pricing to Support Stable Supply
June 23, 2026
- Yoshida Pharma Plant Hit with Improvement Order over Testing Violations
June 23, 2026
- Japan Approves Wegovy MASH Use, AstraZeneca’s Etcamah, Others
June 22, 2026
- Japan on Alert over US MFN Drug Pricing Policy: Health Minister
June 22, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…